5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study
about
Colitis-associated colon cancer: Is it in your genes?Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsUlcerative colitis-associated colorectal cancerDifferential response of flat and polypoid colitis-associated colorectal neoplasias to chemopreventive agents and heterocyclic aminesThe therapeutic value of targeting inflammation in gastrointestinal cancersMesalazine in inflammatory bowel disease: a trendy topic once again?The actin-bundling protein fascin is overexpressed in inflammatory bowel disease and may be important in tissue repairCost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.Cancer surveillance strategies in ulcerative colitis: the need for modernization.Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study.Colonography by CT, MRI and PET/CT combined with conventional colonoscopy in colorectal cancer screening and staging.5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysisChemopreventive effects of 5-amino salicylic acids on inflammatory bowel disease-associated colonic cancer and colonic dysplasia: a meta-analysis.Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasiaUpdate on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates.Systematic review: the use of mesalazine in inflammatory bowel disease.Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey.Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis.Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease.Update in the treatment of paediatric ulcerative colitis.The role of mesalamine in the treatment of ulcerative colitis.Late-breaking news from the "4th International Meeting on Inflammatory Bowel Diseases" Capri, 2006.Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family RegistryQuality of life of patients with ulcerative colitis: past, present, and future.The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ.Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colonCost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease.Targeting NF-kappaB for colorectal cancer.Chemoprophylaxis in colorectal cancer: current concepts and a practical algorithm for use.Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia.The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study.MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis.Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.Potential avenues for immunotherapy of colitis-associated neoplasia.Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.
P2860
Q26778018-F652F864-C809-4C9C-B2D6-3D5C5DEC923DQ26785537-C8609BEE-6C2E-4AE2-AABC-46B8540FB8ABQ26822499-9DB7440A-8EAD-4286-A433-9750AD77B15DQ26864562-82C97591-F91E-40B2-B42E-966E40D1DFB2Q27024203-3A15A376-AFED-4B87-9A76-4C8D8662A96BQ33779797-F2BB7134-8702-4A99-88AD-45D936A879E1Q33827631-346AEF07-73E0-422B-BCED-2B030704BB85Q33950898-D6E3DED7-ED32-4E54-8DCF-E63F7D6D51ABQ34150651-5697F973-F1FD-47B9-AA2D-F8F4A4C6D39CQ34275396-8C9C8E67-DBC2-4A67-8134-493F94D4FA82Q34587817-911CE575-285D-4B4E-AE96-564001A2717CQ35142116-2935103E-18E0-4094-92C6-718BF92E5272Q35619921-49308B45-7008-4E65-8629-F4FF38E2444CQ35943219-2F967F9E-414B-4062-897A-D05650FA42BFQ36144377-85132B75-56DA-4667-86E2-DECD29978DC2Q36367384-F0DDDE03-D1BF-45A0-A501-481ECC502CEAQ36435889-9C7B58CD-C2B8-44D6-B3EA-C8DDC0CBAA23Q36468969-DE083640-B748-4AB8-8F24-718DA3F3E915Q36555966-96CE1ED0-486B-43C6-B4BD-906473BA9092Q36580628-3A0DAF2C-6EFB-4AE3-8B93-747BB7F03EE3Q36589432-1B9B218C-40F8-407D-8D23-09648EB58590Q36613876-A957B668-0421-434C-88C9-7C533771DCA3Q36645826-2BE6445D-CFA9-4591-80D9-7B3C28296FC2Q36739682-72B73AAA-B64D-4D77-92B6-C9576FBFA57DQ36747550-09CBDFB9-78F9-4562-91F6-4E1406C1F44CQ36897912-F7A69A8B-EEB2-42EF-AE69-F7397BBFA1CCQ36987080-D89CDBCA-ABAF-43EA-BFAA-A4EA011060A7Q37262181-B816D1BA-C87F-46F9-A8B1-C6E84065CF09Q37305789-079F20DC-0E16-498D-A3A0-F77083F7944DQ37393339-06D9B860-012F-4B85-A698-AD71A5FBB778Q37692380-8D44CE1E-7DF7-433E-99B9-FB4BA1DCD36DQ37724387-D473EE8B-9150-4C2D-B684-0EEDCADB457AQ37725987-CC1AA4B8-1F7F-46EE-AABB-572E85C190B2Q37786311-9D4A5AF6-B2A3-4963-8B59-35B555C0F22AQ37806620-A9E70620-4D57-4766-A740-A07642746FDEQ37833064-34A0D0D8-A442-4DBE-8D96-29BD9CEE4704Q37885729-DF7E318E-1BA1-4534-8AB1-24EFDC39A7B8Q37892884-B24267FB-666D-47EE-9D36-12836AEE62DAQ38003476-2EE149C7-7010-4646-B3D4-C8CDC4AFCC3BQ38049779-E1056A58-41AF-4CB5-80FD-CA52756879E2
P2860
5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
5-Aminosalicylate use and colo ...... a large epidemiological study
@ast
5-Aminosalicylate use and colo ...... a large epidemiological study
@en
5-Aminosalicylate use and colo ...... a large epidemiological study
@nl
type
label
5-Aminosalicylate use and colo ...... a large epidemiological study
@ast
5-Aminosalicylate use and colo ...... a large epidemiological study
@en
5-Aminosalicylate use and colo ...... a large epidemiological study
@nl
prefLabel
5-Aminosalicylate use and colo ...... a large epidemiological study
@ast
5-Aminosalicylate use and colo ...... a large epidemiological study
@en
5-Aminosalicylate use and colo ...... a large epidemiological study
@nl
P2093
P2860
P921
P356
P1433
P1476
5-Aminosalicylate use and colo ...... a large epidemiological study
@en
P2093
H G M Leufkens
T P van Staa
P2860
P304
P356
10.1136/GUT.2005.070896
P407
P577
2005-11-01T00:00:00Z